About us
StemInov is a French biotechnology company founded in 2019 as a spin-off of the Nancy Regional University Hospital (CHRU de Nancy) and the University of Lorraine. The company develops a proprietary 3D bioproduction platform for mesenchymal stem cells, designed to deliver off-the-shelf allogeneic therapies at clinical scale.
Its lead candidate, WhartSep®, is a Wharton’s jelly mesenchymal stem cell therapy targeting severe community-acquired pneumonia associated with ARDS and sepsis. StemInov is based in Vandœuvre-lès-Nancy, France.
StemInov boards benefit from complementary expertise in business and science
Julie
HUTIN
CEO founder
MBA (EM Lyon Business School), École Centrale de Lyon, 5 years at Eurofins Genomics, HEC Challenge+ 2020-22
Danièle
BENSOUSSAN
Scientific founder
Head of Cellular Therapy Unit (UTCT), CNRS Researcher, Inventor on StemInov patents, 80+ ATMP publications
Alexandre
KORESSIOS
Board member
Partner at Finovam Gestion, Venture Capital Investor, 20+ years in startup financing and deep-tech investments
Hugues
RENAUT
Board member
Business Angel, Healthcare Investor, Angels Santé Board Representative, extensive experience in biotech financing and due diligence
Pierre
TREFFEL
Board member
Founder of Codexial Laboratoire Dermatologique, Entrepreneur, Life Sciences Investor
Pierre Emmanuel CHARLES
ICU DIJON
Eric CHETAILLE
Interim CMO
Robust patent portfolio covers largely Steminov’s unique bioproduction process and the therapeutic applications
Large-scale mastered and protected production
Indication protection
+ IP strategy on the bioproduction platform and additional indications
Partners
R&D
Support
Labels
